1H-咪唑-4-羧酸二甲酰胺 | 56486-26-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1H-咪唑-4-羧酸二甲酰胺
• 英文名称: N,N-dimethyl-1H-imidazole-5-carboxamide
• CAS: 56486-26-1
• 化学式: C₆H₉N₃O
• 分子量: 139.157
• InChiKey: JULPEDSLKXGZKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1H-咪唑-4-羧酸二甲酰胺 在 lithium hydroxide monohydrate 、 水 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 2-(5-(dimethylcarbamoyl)-1H-imidazol-1-yl)acetic acid
  参考文献：
  名称：

  Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors

  摘要：

  Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers. Consequently porcupine inhibitors are thought to be promising oncology therapeutics. A high throughput screen against porcupine revealed several potent hits that were confirmed to be Wnt pathway inhibitors in secondary assays. We developed a pharmacophore model and used the putative bioactive conformation of a xanthine inhibitor for scaffold hopping. The resulting maleimide scaffold was optimized to subnanomolar potency while retaining good physical druglike properties. A preclinical development candidate was selected for which extensive in vitro and in vivo profiling is reported.

  DOI：

  10.1021/acs.jmedchem.7b00662
• 作为产物：
  描述：

  二甲胺 、 1H-咪唑-5-羰酰氯 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 1H-咪唑-4-羧酸二甲酰胺
  参考文献：
  名称：

  Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors

  摘要：

  Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers. Consequently porcupine inhibitors are thought to be promising oncology therapeutics. A high throughput screen against porcupine revealed several potent hits that were confirmed to be Wnt pathway inhibitors in secondary assays. We developed a pharmacophore model and used the putative bioactive conformation of a xanthine inhibitor for scaffold hopping. The resulting maleimide scaffold was optimized to subnanomolar potency while retaining good physical druglike properties. A preclinical development candidate was selected for which extensive in vitro and in vivo profiling is reported.

  DOI：

  10.1021/acs.jmedchem.7b00662

文献信息

• Synthesis of antimicrobial agents. 1. Syntheses and antibacterial activities of 7-(azole substituted)quinolones
  作者：Toshio Uno、Masanori Takamatsu、Yoshimasa Inoue、Yoshihiro Kawahata、Koji Iuchi、Goro Tsukamoto

  DOI：10.1021/jm00395a001

  日期：1987.12

  Structure-activity relationship studies indicated that the antibacterial potency was better when the 6,8-substituents were fluorine atoms and the 7-substituent was either 1-imidazolyl, 20, or 4-methyl-1-imidazolyl, 25. From the results of studies on pharmacokinetic profile and toxicity, 20 and 25 were found to possess excellent antibacterial activities and to show high blood levels after oral administration

  制备了一系列6-氟-和6,8-二氟-7-（唑取代的）-1,4-二氢-4-氧代-3-喹啉羧酸。结构活性关系研究表明，当6,8-取代基是氟原子，而7-取代基是1-咪唑基20或4-甲基-1-咪唑基25时，抗菌效果更好。在药代动力学和毒性研究中，发现20和25具有出色的抗菌活性，并且对低毒性小鼠口服后显示出较高的血药浓度。
• GYRASE INHIBITORS AND USES THEREOF
  申请人：Charifson PAUL

  公开号：US20090325955A1

  公开（公告）日：2009-12-31

  The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.

  本发明涉及使用化合物I或化合物VII或其药学盐在哺乳动物中治疗、预防或减轻耐药细菌感染的方法。本发明还涉及使用化合物I或化合物VII与一个或多个额外的抗菌剂和/或一个或多个增加细菌对抗生素敏感性的治疗剂相结合的方法。
• Gyrase Inhibitors and Uses Thereof
  申请人：Charifson Paul

  公开号：US20120010222A1

  公开（公告）日：2012-01-12

  The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.

  本发明涉及使用I式或VII式化合物或其药学盐治疗、预防或减轻哺乳动物中耐药细菌感染的方法。本发明还涉及使用I式或VII式化合物与一种或多种额外的抗菌剂和/或一种或多种增加细菌对抗生素易感性的治疗剂联合使用的方法。
• NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF
  申请人：Shanghai Yingli Pharmaceutical Co. Ltd.

  公开号：EP3492461A1

  公开（公告）日：2019-06-05

  Provided are a nitrogenous heterocyclic aromatic compound, a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The nitrogenous heterocyclic aromatic compound can be used for treating and/or preventing various diseases mediated by ALK5.

  本文提供了一种含氮杂环芳香化合物、其制备方法、药物组合物及其应用。该含氮杂环芳香化合物可用于治疗和/或预防由 ALK5 介导的各种疾病。
• Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US11466003B2

  公开（公告）日：2022-10-11

  Provided are a nitrogenous heterocyclic aromatic compound, a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The nitrogenous heterocyclic aromatic compound can be used for treating and/or preventing various diseases mediated by ALK5.

  本文提供了一种含氮杂环芳香化合物、其制备方法、药物组合物及其应用。该含氮杂环芳香化合物可用于治疗和/或预防由 ALK5 介导的各种疾病。